Lecture Details - Table of Contents

26th Annual Miami Breast Cancer Conference
Day 4 Main Conference

Release Date: March 8, 2009| Mar 7, 2009, Miami, FL

Table of Contents

Guidelines for Preoperative Therapy: A Multidisciplinary Approach
Michael Untch

Relevance of Age and ER Status to Benefit From Preoperative Chemotherapy vs. Postoperative Chemotherapy
Norman Wolmark

Preoperative Endocrine Therapy
Matthew Ellis

How Do You Measure Residual Breast Cancer and Its Relationship to Survival: Is Residual Tumor Enhanced for Stem Cells?
William F. Symmans

Cancer Stem Cells: Opportunities for New Therapeutic Modalities
Emanuel Petricoin

What Determines the Sites of Metastases, and Is It Hardwired Into Primary Tumor?
Debu Tripathy

Response of Triple-Negative Tumors to Preoperative Chemotherapy: Prognostic Markers to Identify Tumors With More Aggressive Behavior
Lisa Carey

New Insights Into the Biology and Management of Inflammatory Breast Cancer
Hyman B. Muss

Surgical Options After Preoperative Systemic Therapy
J. Michael Dixon

Locoregional Treatments After Preoperative Chemotherapy
Timothy Whelan

Surgical Management of Lymphedema
Sumner Slavin

Panel Discussion With Case Presentations
Moderator:
Robert DerHagopian
Panel:
Alan Ashworth
Lisa Carey
Matthew Ellis
Hyman B. Muss
Emanuel Petricoin
Lajos Pusztai
Sumner Slavin
Michael Untch
Timothy Whelan
Norman Wolmark

Instructions for Participation

To view the streaming Flash Video lectures, click the "View Flash Presentation" link. The latest version of Flash Player is recommended to view the Flash video.
Click here to download Flash Player >>

To download Podcast-ready movies, click "Download Video Podcast," and select "Save target as..." The latest version of Quicktime is recommended to view these movies.
Click here to download Quicktime >>

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclaimer
Physicians’ Education Resource presents this resource for educational purposes only. Participants are expected to use their own expertise and judgment while engaged in the practice of medicine. Please consult full prescribing information for any drugs or procedures discussed within.

The views and opinions expressed in these presentations are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Disclosure of Unlabeled Uses
This reference may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.

All rights reserved; for personal use only. No part of this presentation may be translated, reproduced or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Educational Grants

An educational grant for this activity was provided by:


  1. Educational Partners
  2. Genentech BioOncology
  3. GlaxoSmithKline
  5. Major Contributors
  6. AstraZeneca/Abraxis BioScience
  7. Bristol-Myers Squibb
  8. Novartis Oncology
  9. sanofi-aventis U.S.
  11. Supporters
  12. Amgen
  13. Centocor Ortho Biotech Inc.
  14. ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
  16. Honorary Supporter
  17. Joe’s Stone Crab Restaurant